rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ADPT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Adaptive Biotechnologies at Jefferies Global Healthcare Conference: growth broadens
      10h agoInvesting.comADPTJEF
      Adaptive Biotechnologies CCO Bobulsky sells $60,000 in stock
      Nov 14Investing.comADPT
      Adaptive Biotechnologies COO Julie Rubinstein sells $708,557 in stock
      Nov 11Investing.comADPT
      Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
      Nov 10Yahoo FinanceADPT
      Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
      Nov 10Yahoo FinanceADPT
      Adaptive Biotechnologies stock hits 52-week high at 30.74 USD
      Nov 9Investing.comADPT
      Adaptive Biotechnologies (ADPT) Reported Mixed Q3 Results, Is The Stock Fully Valued?
      Nov 8Yahoo FinanceADPT
      Adaptive Biotechnologies president and COO Julie Rubinstein sells $954k stock
      Nov 7Investing.comADPT
      Adaptive (ADPT) Q3 2026 Earnings Call Transcript
      Nov 5The Globe and MailADPT
      Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable Quarter ...
      Nov 5Yahoo FinanceADPT
      Adaptive Biotechnologies earnings beat by $0.11, revenue topped estimates
      Nov 5Investing.comADPT
      Adaptive Biotechnologies Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceADPT
      Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates
      Nov 4Yahoo FinanceADPT
      Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Nov 4Yahoo FinanceADPT
      Adaptive Biotechnologies Q3 2026 Earnings Call Transcript
      Nov 4BenzingaADPT
      Adaptive Biotechnologies: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceADPT
      Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
      Nov 4Yahoo FinanceADPT
      Adaptive Biotechnologies earnings on deck amid guideline tailwinds
      Nov 4Investing.comADPT
      Adaptive Biotechnologies president and COO Julie Rubinstein sells $928,891 in stock
      Nov 4Investing.comADPT
      Adaptive Biotechnologies president Julie Rubinstein sells $998k in shares
      Oct 30Investing.comADPT
      Adaptive Biotechnologies Corp. (ADPT) Rallies on Earnings Beat, Raised Outlook, and Cash-Flow Targets
      Oct 27Yahoo FinanceADPT
      Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure (ADPT)
      Oct 27Seeking AlphaADPT
      Adaptive Biotechnologies president and COO Julie Rubinstein sells $897k shares
      Oct 27Investing.comADPT
      Adaptive Biotechnologies Insider Sold Shares Worth $879,088, According to a Recent SEC Filing
      Oct 22Yahoo FinanceADPT
      Adaptive Biotechnologies president and coo Julie Rubinstein sells $879,088 in shares
      Oct 21Investing.comADPT
      Adaptive biotechnologies president & COO Rubinstein sells $897k stock
      Oct 17Investing.comADPT
      Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
      Oct 14Yahoo FinanceADPT
      Adaptive Biotechnologies COO Julie Rubinstein sells $919,870 in stock
      Oct 13Investing.comADPT
      Adaptive Biotechnologies CCO Susan Bobulsky sells $193,320 in stock
      Oct 8Investing.comADPT
      Adaptive Biotechnologies COO Julie Rubinstein sells $948,223 in stock
      Oct 8Investing.comADPT
      Adaptive Biotechnologies (ADPT) Stock Sees Modest Fair Value Lift On MRD Optimism
      Oct 8Yahoo FinanceADPT
      Adaptive Biotechnologies stock hits 52-week high at $30.10
      Oct 6Investing.comADPT
      Adaptive Biotechnologies Insider Sold Shares Worth $1,014,329, According to a Recent SEC Filing
      Oct 6Yahoo FinanceADPT
      Adaptive Biotechnologies COO Julie Rubinstein sells $1m in stock
      Oct 6Investing.comADPT
      Adaptive biotechnologies CPO Francis Lo sells $757k in shares
      Oct 6Investing.comADPT
      Goldman Sachs initiates Adeptus Biotechnologies stock with buy rating
      Sep 29Investing.comADPT
      Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock
      Sep 28Investing.comADPT
      Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update

      Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride. With the stock recently closing at US$29.57 and investor attention drawn to new clinical guideline support for its testing platform, the focus turns to what the current valuation says about its future cash streams. Over the past 3 years the stock has returned about 432.8%, which puts a lot of weight on the...

      Sep 25Yahoo FinanceADPT
      Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

      Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cellsSEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multi

      Sep 25Yahoo FinanceADPT
      Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

      Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company’s clonoSEQ assay. Investors have reacted quickly to the guideline update, with Adaptive Biotechnologies’ share price up 6.02% over the past day and posting a 12.65% 30-day share price return, while the 1-year total shareholder return of 125.21% and 3-year total shareholder...

      Sep 25Yahoo FinanceADPT
      Adaptive Biotechnologies stock hits 52-week high at 28.79 USD
      Sep 24Investing.comADPT
      NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

      Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleared clonoSEQ assay with preferred high-sensitivity thresholds and expanded testing timepoints. The inclusion of clonoSEQ by name, alongside broader recommendations for routine and longitudinal MRD assessment, strengthens its position as a standardized tool...

      Sep 24Yahoo FinanceADPT
      Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

      Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines. The update strengthens the case for monitoring minimal residual disease, or […]

      Sep 23Yahoo FinanceADPT
      Adaptive Biotechnologies Insider Sold Shares Worth $3,238,004, According to a Recent SEC Filing

      Francis Lo, Chief People Officer, on September 16, 2026, sold 115,406 shares in Adaptive Biotechnolo

      Sep 21Yahoo FinanceADPT
      Analysts Conflicted on These Healthcare Names: Envista Holdings (NVST), Alpha Teknova (TKNO) and Adaptive Biotechnologies (ADPT)

      Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailADPTTKNONVST
      Adaptive Biotechnologies CPO Francis Lo sells $3.2m in stock
      Sep 19Investing.comADPT
      Adaptive biotechnologies chief commercial officer sells $32,265 in shares.
      Sep 18Investing.comADPT
      Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

      Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted signifi

      Sep 17Yahoo FinanceADPT
      Adaptive Biotechnologies stock hits 52-week high at 26.89 USD
      Sep 15Investing.comADPT
      Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

      SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 20

      Sep 1Yahoo FinanceADPTMS

      This is the newest page. Registered accounts read further back.